T1	Participants 605 786	The 101 eligible cases (bestatin: 48, control: 53) were analyzed; the bestatin group achieved longer remission than the control group and a statistically significant longer survival
T2	Participants 0 106	Randomized controlled study of chemoimmunotherapy with bestatin of acute nonlymphocytic leukemia in adults
